Production & Manufacturing
BioPharma
Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition
uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.
The cell & gene therapy (CGT) CDMO...
News
UNDBIO to Build $100M Insulin Manufacturing Facility in West Virginia
UNDBIO, a South Korean pharmaceutical company focused on diabetic care, will spend $100 million to build an insulin manufacturing facility in West Virginia.
The project is expected to create 200 new jobs in the first three years, according to an April...
Press Releases
Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation
Lonza announces the start of new mid-scale manufacturing assets at its API manufacturing center in Nansha, China. Commercial mid-scale operations are now underway at the expanded manufacturing facility, which was part of a CHF 20 million investment announced in...
News
How ‘First-Time Right’ Formulations Can Help Address the Challenge of Affordable Medicines
For years, global healthcare systems have been facing the triple threat of rising incidences of long-term conditions (LTC), aging populations and dwindling resources. At the same time, we have seen worldwide calls for affordable medicines – from the Jan...
News
By 2030, OSD Contract Manufacturing Will Be $54.7 Billion
The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate (CAGR) of 6%, according to a market analysis.
As per data, oral solids are the...
News
By 2026, Pharma Contract Manufacturing To Be Worth $130bn
The global pharmaceutical contract manufacturing market is anticipated to reach $130.2 billion by 2026 as a result of increasing demand for pharmaceuticals, particularly in developing economies. In 2020, the market was estimated to be worth $100 billion.
Market research indicates...
News
Leanings In The Biopharma Contract Manufacturing For 2022
A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market for biopharmaceutical contract manufacturing.
Over the next ten years, the investigators predict a very bright...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
